Opinions on Gilead Sciences Inc. and GlaxoSmithKline plc -- A Look at R&D in the Health Industry
February 03 2011 - 8:05AM
Marketwired
www.stockcall.com/ offers investors comprehensive research on the
biotechnology industry and has completed analytical research on
Gilead Sciences Inc. (NASDAQ: GILD) and
GlaxoSmithKline plc (NYSE: GSK). Register
with us today at www.stockcall.com/ to have free access to these
researches.
Strengthened regulatory efforts from the Food and Drug
Administration have forced some biotechnology and drug
manufacturers to readjust their approaches to research and
development. Register now at
https://stockcall.com/development/stockcall/page.php?name=register.html
to have free access to our reports on the biotechnology
industry.
www.stockcall.com/ is an online platform where investors doing
their due-diligence on the biotechnology industry can have easy and
free access to our analyst research and opinions on Gilead Sciences
Inc. and GlaxoSmithKline plc; all investors need to do is register
for a complimentary membership at
https://stockcall.com/development/stockcall/page.php?name=register.html.
Drug manufacturers have upped their collaborative efforts with
Universities and looked to acquisitions to get drugs to market
while spending less on R&D. Partnerships with Universities give
drug makers the first opportunity at new technology in exchange for
funding development. Visit www.stockcall.com/ to see how companies
in this industry have grown over the past years and how they are
expected to perform in the future.
Both Biotech and drug manufacturers have felt greater pressure
to get products and drugs to market faster to generate revenue in a
weaker economic environment. While autonomous developments yield
the greatest returns, they require time, a luxury few companies
within the industry have at the moment. Regulatory delays like the
FDA's recent decline of an HIV drug marketing application for
Gilead Sciences Inc. can upset revenue projections and have only
made it more important for companies to get the most out of R&D
dollars. Investors looking for free research on Gilead Sciences Inc. are welcome to sign up at
www.stockcall.com/GILD030211.pdf.
Some companies are also delaying R&D on projects to ensure a
greater likelihood of getting them through the costly approval
process. GlaxoSmithKline announced the discontinuation of clinical
trials of an insomnia drug this week to conduct further research.
Investors looking for free research on GlaxoSmithKline plc are welcome to sign up at
www.stockcall.com/GSK030211.pdf.
Overall, a greater sense of urgency to get products to market is
affecting companies' attitudes towards R&D. Companies getting
the greatest return on R&D dollars or that are effectively
using alternative means to get products to market could be best
positioned for growth moving forward.
About StockCall.com StockCall.com is a
financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the
headlines.
Contact Person: William T. Knight
stockcall2010@gmail.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024